Combination of dual JAK/HDAC inhibitor with regorafenib  reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer
To evaluate the differential  gene expression contributing to the efficacy of the combination treatment of JAK/HDAC inhibitor with regorafenib, compared to single drug treatment,  we performed the RNA-sequencing Overall design: SW480 cells were treated at 500nM concentration of JAK/HDACi and regorafenib as single drugs, and their combination. Dmso was used as control.